Precision Med’s Post

In our latest Oncology Consortia newsletter, learn about a peer-reviewed research paper in Cancer Discovery about the discovery and preclinical to clinical translation for RMC-6236, an investigational RAS(ON) multi-selective inhibitor. Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). https://bit.ly/4bs4yr9 #clinicaltrial #oncology #clinicaltrialnews

Could ADCs be a game-changer for oncology? New cancer drugs based on ADCs have shown promising results in shrinking hard-to-treat tumors in mice. This innovative therapy targets cancer cells' waste disposal system, leading to their self-destruction. 3 Key Takeaways: - This approach disrupts a novel cellular process, offering a fresh perspective on cancer treatment. - Early results in mice are encouraging, but further research is needed to assess safety and efficacy in humans. - This discovery highlights the continuous advancements in cancer research, offering hope for future breakthroughs. What are your thoughts on this new therapeutic approach? #LifeSciences #Oncology #CancerResearch #DrugDiscovery #Innovation #Breakthrough https://lnkd.in/eY-Bnrqf

Exciting new research in the field of bladder cancer! A recent systematic review and meta-analysis delves into the clinicopathological significance of B7-H3, a potential biomarker for prognosis and treatment in bladder cancer. The study uncovers key insights into B7-H3 expression in tumor tissues, patient age, and recurrence. However, the link to overall survival remains uncertain. A must-read for oncology professionals seeking in-depth knowledge of bladder cancer biomarkers. #BladderCancer #B

In a recently published study in American Association for Cancer Research's Cancer Discovery, “Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy,” researchers found that deliberate hyperactivation of oncogenic signaling shows promise in #cancer treatment.   Treatments typically try to stop signals that make cancer grow. But this research found that sometimes making those signals stronger can actually kill cancer cells. Acquired resistance to the combination of #Lixte Biotechnology’s #LB100 lead molecule and Adavosertib suppress anchorage-independent and tumor growth in colorectal cancer cell models. Click the link to download the full study and learn how these findings can also help improve future therapies. #Oncology #immunotherapy #chemotherapy https://lnkd.in/gb5ZQswg

Could targeting LAG-3 take cancer immunotherapy to the next level? Dr. Sabi Pabla and Dr. Eric Severson share insights on this promising immune biomarker in the latest Labcorp Perspectives: Oncology interview. Learn how LAG-3 helps tumors evade the immune system and why inhibiting it may enhance existing immunotherapies: http://spr.ly/6049gBQGD #Oncology #Immunotherapy #Biomarkers

At #SITC 2024, AstraZeneca will be presenting 14 abstracts that demonstrate our progress in cancer immunotherapy. A highlight will be the sharing of preclinical data from our novel Target Induced T cell Activating Nanobody (TITAN) platform, including the first disclosure of a TITAN T-cell engager intended for use in solid tumours. Recent advances in our understanding of the immune system are driving the development of the next generation of immunotherapies, and we’re pushing the boundaries of science to reimagine cancer care and help transform outcomes for patients. Find out more our focus areas in immunotherapy here: #Oncology #Tcellengager #celltherapy

At #SITC 2024, AstraZeneca will be presenting 14 abstracts that demonstrate our progress in cancer immunotherapy. A highlight will be the sharing of preclinical data from our novel Target Induced T cell Activating Nanobody (TITAN) platform, including the first disclosure of a TITAN T-cell engager intended for use in solid tumours. Recent advances in our understanding of the immune system are driving the development of the next generation of immunotherapies, and we’re pushing the boundaries of science to reimagine cancer care and help transform outcomes for patients. Find out more our focus areas in immunotherapy here: #Oncology #Tcellengager #celltherapy

At #SITC 2024, AstraZeneca will be presenting 14 abstracts that demonstrate our progress in cancer immunotherapy. A highlight will be the sharing of preclinical data from our novel Target Induced T cell Activating Nanobody (TITAN) platform, including the first disclosure of a TITAN T-cell engager intended for use in solid tumours. Recent advances in our understanding of the immune system are driving the development of the next generation of immunotherapies, and we’re pushing the boundaries of science to reimagine cancer care and help transform outcomes for patients. Find out more our focus areas in immunotherapy here: #Oncology #Tcellengager #celltherapy

Let's catch up about Cell Therapy in Houston at #SITC 2024 😎 AstraZeneca will be presenting 14 abstracts that demonstrate our progress in cancer immunotherapy. A highlight will be the sharing of preclinical data from our novel Target Induced T cell Activating Nanobody (TITAN) platform, including the first disclosure of a TITAN T-cell engager intended for use in solid tumors. Recent advances in our understanding of the immune system are driving the development of the next generation of immunotherapies, and we’re pushing the boundaries of science to reimagine cancer care and help transform outcomes for patients. Find out more our focus areas in immunotherapy here: #SITC24 #Oncology #TcellEngager #CellTherapy #BE #BiologicalEngineering #CARTcells